Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News

CSL Behring Launches My Access™ Cost Share Program

People who are treating hemophilia A or von Willebrand Disease (VWD) with a CSL Behring therapy may now be eligible for financial support through the company’s My Access™ cost share program. My Access helps hemophilia A and VWD patients, who have private insurance, cover the out-of-pocket costs, up to $12,000, associated with treatment. “CSL Behring […]

Canada Approves Biogen Idec’s Long-Acting Alprolix™ for Hemophilia B

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years Today Biogen Idec announced that Health Canada has approved ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. […]

PSI: CMS Final Rule On Ryan White Premium Assistance & Other State/Federal Programs

The Centers for Medicare and Medicaid Services (CMS) has posted an interim final rule (IFR) with comment period requiring Qualified Health Plans (QHPs) to “accept premium and cost-sharing payments made on behalf of enrollees by the Ryan White HIV/AIDS Program, other Federal and State government programs that provide premium and cost sharing support for specific […]

CMS Explanation in Response to PSI Letter to HHS Secretary

In response to letters by Patient Services Incorporated (PSI) and other patient advocacy groups, CMS has released a further explanation on the November 4, 2013, Frequently Asked Question (FAQ) document. As you will remember, CMS called into question the use of premium assistance, the FAQ stated: The Department of Health and Human Services (HHS) has […]

Bayer: Postive Results from Phase III Study of Long-Acting Recombinant Factor VIII

Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company’s investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the site-specific PEGylated factor VIII helped protect against bleeds when used prophylactically every seven […]

Phase IV Study Results for Once-weekly BeneFIX

Adding to the growing body of published data on treatment paradigms in hemophilia B, the January edition of Haemophilia published data from a multicenter, randomized, cross-over Phase IV study demonstrating that secondary prophylaxis using once-weekly 100 IU/kg BeneFIX® Coagulation Factor IX (Recombinant) provided a similar efficacy and safety profile compared with twice-weekly prophylaxis at 50 […]

Applications Open: Bayer Hemophilia Leadership Development Program

The Bayer Hemophilia Leadership Development Program (BHLDP) provides college students from the hemophilia community a unique internship opportunity to build foundational leadership skills while also deepening their connection to the hemophilia community. BHLDP, now in its eighth year, gives selected interns an opportunity to work directly with the Bayer marketing team in Whippany, New Jersey. […]

Flint-based Diplomat Acquires American Homecare Federation

FLINT, MI (Michigan Live) — Flint-based Diplomat, the country’s largest independent specialty pharmacy, says it has acquired American Homecare Federation, a provider of hemophilia pharmacy services. Diplomat made the announcement in a news release Monday, Jan. 13, saying all AHF employees will continue in their current roles. AHF is based in Enfield, Conn. “Diplomat is […]

Biogen Idec Announce Global Collaboration to Develop Treatment for Hemoglobinopathies

Cambridge, Mass and Richmond, Calif. – Biogen Idec (NASDAQ:BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The agreement will enable Biogen Idec to further enhance its expertise […]

FDA Approves Treatment Option for Congenital Factor XIII A-Subunit Deficiency

Novo Nordisk is pleased to announce that the US Food and Drug Administration (FDA) has approved TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency, one of the rarest inherited bleeding disorders. TRETTEN® is the only recombinant treatment for the disease. Patients with […]

Page 5 of 1612345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community